Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RM-493 in Healthy Obese and MC4R Deficient Volunteers
NCT02431442Phase 1Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jan 2012
- Primary completion
- Jan 2014
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of setmelanotide in obesity (12 cohorts), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Number of adverse events. Started Jan 2012; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02431442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431442.